Ignite Creation Date:
2024-05-05 @ 4:44 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00304590
Status:
TERMINATED
Last Update Posted:
2010-02-22
First Post:
2006-03-16
Brief Title:
Study of XL999 in Patients With Multiple Myeloma
Sponsor:
Symphony Evolution Inc
Organization:
Symphony Evolution Inc
Study Overview
Official Title:
A Phase 2 Study of XL999 in Subjects With RelapsedRefractory Multiple Myeloma
Status:
TERMINATED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study was terminated due to cardiac toxicities in the subjects
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical study is being conducted at multiple sites to determine the activity safety and tolerability of XL999 when given weekly to patients with relapsed or refractory multiple myeloma XL999 is a small molecule inhibitor of cellular factors including VEGFR PDGFR and FGFR that may be involved in multiple myeloma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None